Prevention of thromboembolic phenomena

Area of Science:

• Orthopedic Surgery
• Vascular Surgery
• Pharmacology

Background:

• Pulmonary embolism (PE) is the primary cause of mortality following total hip replacement (THR).
• Current prophylactic anticoagulation methods reduce thromboembolic events but carry significant complication risks.
• Optimizing prophylaxis for THR patients is crucial to balance efficacy and safety.

Purpose of the Study:

• To evaluate the safety and effectiveness of a combined low-dose warfarin prophylaxis and non-pharmacological management strategy in reducing thromboembolic complications after THR.
• To assess the incidence of clinical thrombosis, pulmonary emboli, and associated mortality in patients undergoing THR.

Main Methods:

• A cohort of 415 patients undergoing total hip replacement received a prophylactic regimen.
• The regimen included low-dose warfarin, anti-embolic hose, leg elevation, and early ambulation.
• Outcomes monitored included clinical thrombosis, pulmonary emboli, mortality, and systemic/wound complications.

Main Results:

• A low incidence of clinical thrombosis (2.4%) and pulmonary emboli (1.45%) was observed, with no fatal PE.
• Overall mortality was low at 0.49%, with deaths attributed to non-embolic causes.
• Systemic warfarin complications were minimal (5 mild gastrointestinal hemorrhages); wound hemorrhage occurred in 4.6%.

Conclusions:

• The integrated management program, combining low-dose warfarin with supportive measures, is safe and effective in preventing fatal postoperative pulmonary emboli after total hip replacement.
• Close patient monitoring is essential to manage potential complications, such as wound hemorrhage requiring surgical evacuation.
• This strategy offers a promising approach to reduce mortality in THR patients while minimizing anticoagulation-related risks.